Researchers indicate polyurethane catheters, such as those used in Bard PowerPort implants, often lead to early device failure and infections.
Judge compared Bard PowerPort lawsuits to IVC filter litigation, where the majority of cases were filed more than 18 months after the claims were consolidated into a MDL
Of the 25 Bard chemo port devices on the market, at least 15 have been identified in lawsuits filed over failures, infections and other complications among individuals who received the implantable port catheter.
The outcome of the early bellwether test trials could impact the average Bard Power Port lawsuit settlement amounts the manufacturer may need to pay to avoid hundreds of claims being remanded for individual trials.
Judge has approved a new streamlined process for plaintiffs to file Bard Power Port lawsuits directly in the U.S. District Court for the District of Arizona, where the federal litigation is centralized.
The presiding judge has determined that six Bard PowerPort lawsuits will ultimately be chosen for the first bellwether trials.
About a dozen incompatibility problems with Alaris infusion pumps and Cardinal Health Monoject syringes have been reported.
Lawsuit indicates that the failure to warn patients and the medical community about the risk of Bard PowerPort complications contributed to the development of a life-threatening infection for an Illinois woman.
Plaintiffs and defendants suggest an initial pool of 48 Bard PowerPort lawsuits be selected as part of an initial discovery pool, which will be prepared for a series of early trial dates in the federal Multidistrict Litigation (MDL)
Manufacturers allegedly withheld information from patients and the medical community about problems with the port catheter design, which increased the risk of Bard PowerPorts becoming infected
